ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 12, 2016
Boasting a price of $5.28, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) traded -3.04% lower on the day. With the last stock price close down -16.60% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. ZIOPHARM Oncology Inc. has recorded a 50-day average of $5.45 and a two hundred day average of $6.30. Volume of trade was down over the average, with 1,094,337 shares of ZIOP changing hands under the typical 1,988,780
Zacks Investment Research has downgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Hold in a statement released on 10/12/2016.
On 8/16/2016, Zacks Investment Research released a statement for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) bumped up the target price from $0.00 to $6.50 that suggested an upside of 0.10%.
With a total market value of $0, ZIOPHARM Oncology Inc. has with a one year low of $4.45 and a one year high of $14.93 .
A total of 2 equity analysts have released a research note on ZIOP. One equity analyst rating the company a strong buy, zero equity analysts rating the company a buy, three equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally one equity analyst rating the company a sell with a one year target of $14.00.
Brief Synopsis About ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company's Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.